Compare CVS Health Corp (CVS) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Kyndryl Holdings Inc — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Kyndryl Holdings Inc trades at $11.76 (market cap $2.49B). The key difference: CVS Health Corp is far larger — about 45.2× Kyndryl Holdings Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Kyndryl Holdings Inc for 36 Days on average.
| CVS | KD | |
|---|---|---|
Market Cap | $112.49B | $2.49B |
Volume | 8,467,392 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $110.60 | $29.76 |
52-Week Low | $70.08 | $10.59 |
Typical Hold Time | 83 Days | 36 Days |
Enterprise Value | $174.83B | $5.32B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Kyndryl (KD) trades at $11.88, up 3.48% today, with a bearish technical signal and mixed earnings. Revenue declined to $15.06B in 2025, but net income turned positive at $252M, marking a recovery from prior losses. The company is actively investing in AI, as highlighted by recent news of an AI innovation lab and acquisitions. Analyst consensus is mostly hold, with a $14.67 price target suggesting moderate upside.
The outlook hinges on AI-driven growth offsetting revenue pressures, but risks include high debt, competitive IT services market, and inconsistent earnings. Institutional sentiment is cautious, with weak technical trends near key support. Upside depends on execution of modernization contracts and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
